Results 181 to 190 of about 134,892 (289)

Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma

British Journal of Haematology, EarlyView.
This study examined the effect of MYD88L265P (myeloid differentiation primary response gene 88 mutation L265P) and/or CD79BY196 (cluster of differentiation 79B gene mutation Y196) on central nervous system (CNS) relapse in 270 patients with newly diagnosed diffuse large B‐cell lymphoma.
Tomotaka Suzuki, Keiichiro Fujii, Naohiro Matsunaga, Hirokazu Sasaki, Takashi Kanamori, Arisa Asano, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki   +14 more
wiley   +1 more source

The investigation of apoptosis-related genes in periodontitis. [PDF]

BMC Res Notes
Sayad A, Hashemian F, Gholami L, Jamali M, Badrlou E, Sadeghpour S, Nazer N, Khalilian S, Ghafouri-Fard S.   +8 more
europepmc   +1 more source

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort

British Journal of Haematology, EarlyView.
The international prognostic index (IPI)‐driven trial inclusion criteria may have contributed to the failure of some of the first‐line trials in large B‐cell lymphoma (LBCL). GLA and LYSA collaborated to improve prognostic stratification in LBCL by analyzing data from trial cohorts and proposed the smIPI.
Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç, Ebru Pekgüç, Taner Tan, Eda Nuhoğlu Kantarcı, Metban Mastanzade, Ali Durdu, Merve Apaydın Kayer, Murat Özbalak, Tuğrul Elverdi, Asu Fergün Yılmaz, Deniz Gören, Tayfur Toptaş, Turgay Ulaş, Özgür Mehtap, Mehmet Sinan Dal, Olga Meltem Akay, Muhlis Cem Ar, Güray Saydam, Fevzi Altuntaş, Elif Birtaş Ateşoğlu, Burhan Ferhanoğlu   +24 more
wiley   +1 more source

Anti-BCL2 therapy eliminates giant congenital melanocytic nevus by senolytic and immune induction. [PDF]

Signal Transduct Target Ther
Wei B, Yu Q, Jin J, Zhu D, Lai B, Gu J, Yang R, Huang H, Lin H, Zhang L, Zan T, Xie F, Zhang K, Li Q.   +13 more
europepmc   +1 more source

Immunohistochemical Expression of BCl2 Oncoprotein in Varying Histological Grades of Oral Squamous Cell Carcinoma

Online Journal of Health & Allied Sciences
Oral cancer has been rising in alarming numbers in the world which is anticipated to escalate at 70% by 2030. Although a lot of factors are responsible for the disease, genetics, and gene mutations play a major role in uncontrolled proliferation. Another
Subhalakshmi V, Rohit Jaiswal, Indra Priyadharshini K, Ambika Murugesan   +3 more
doaj  

An international real‐world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators

British Journal of Haematology, EarlyView.
Primary vitreoretinal lymphoma is an incredibly rare non‐Hodgkin lymphoma with no clear international consensus guidelines for diagnosis and management. This study highlights the significant real‐world heterogeneity in diagnostic and management approaches of this rare condition. In particular, the incorporation of systemic therapy to initial management
Catherine Tang, Catriona Downie, Mandeep S. Sagoo, Edward Pringle, Adam Suleman, Katharine L. Lewis, Lucy Zhang, Daire Quinn, L. M. Poon, William Hann, Svetlana Cherepanoff, Luke Coyle, Shireen Kassam, Pamela McKay, Chan Y. Cheah, Anca Prica, Jeffery Smith, Nada Hamad   +17 more
wiley   +1 more source

Correction: Centella asiatica mitigates the detrimental effects of Bisphenol-A (BPA) on pancreatic islets. [PDF]

Sci Rep
Banerjee O, Singh S, Paul T, Maji BK, Mukherjee S.   +4 more
europepmc   +1 more source

Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches

PROTEOMICS, EarlyView.
Paul Perco, Matthias Ley, Kinga Kęska‐Izworska, Dorota Wojenska, Enrico Bono, Samuel M. Walter, Lucas Fillinger, Klaus Kratochwill   +7 more
wiley   +1 more source

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era. [PDF]

Cancers (Basel)
Chatzilygeroudi T, Karantanos T, Pappa V.   +2 more
europepmc   +1 more source

Dasatinib overcomes AML cells resistant to BCL2 inhibition by degrading MCL1

British Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) is a severe disease occurring mainly in the elderly population. Venetoclax (VEN) combined with azacitidine has changed the paradigm of treatment of AML. Nevertheless, approximately 30% of patients are primary refractory to VEN (VEN‐R), with no current therapeutic option.
Sylvain Garciaz, Camille Montersino, Maxence Bourgoin, Arnaud Jacquel, Rémy Castellano, Arnaud Guille, Max Chaffanet, François Bertucci, Marie‐Anne Hospital, José Adélaïde, Patrick Auberger, Norbert Vey, Yves Collette   +12 more
wiley   +1 more source